Cation exchange chromatography provides effective retrovirus clearance for antibody purification processes

Biotechnology and Bioengineering

Volumn 109, Issue 1, 2012, Pages 157-165

  Connell Crowley, Lisa ^a   Nguyen, Thao ^a   Bach, Julia ^a   Chinniah, Shivanthi ^a   Bashiri, Houman ^a   Gillespie, Ron ^a   Moscariello, John ^a   Hinckley, Peter ^a   Dehghani, Houman ^a   Vunnum, Suresh ^a   Vedantham, Ganesh ^a  

^a AMGEN INC   (United States)

Author keywords

CEX; Monoclonal antibody; Purification; Viral clearance; XMuLV

Indexed keywords

ANTIBODY PURIFICATION; BIOTHERAPEUTICS; CATION EXCHANGE CHROMATOGRAPHY; CATION EXCHANGERS; CEX; CHINESE HAMSTER OVARY CELLS; DESIGN SPACES; DOMINANT MECHANISM; EXPERIMENTAL DATA; MAMMALIAN CELLS; MONOCLONAL ANTIBODIES (MAB); POLISHING STEPS; PURIFICATION PROCESS; VIRAL CLEARANCE; XMULV;

ADSORPTION; CHROMATOGRAPHY; GEL PERMEATION CHROMATOGRAPHY; MAMMALS; MONOCLONAL ANTIBODIES; POSITIVE IONS; PURIFICATION; RESINS; VIRUSES;

IONIC STRENGTH;

CHEMICAL COMPOUND; FRACTOGEL; MONOCLONAL ANTIBODY; RESIN; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL CELL; ARTICLE; CHO CELL; ELUTION; FEMALE; HOST CELL; ION EXCHANGE CHROMATOGRAPHY; IONIC STRENGTH; LIMIT OF DETECTION; NONHUMAN; PH; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; REPRODUCIBILITY; RETROVIRUS; VIRAL CLEARANCE; VIRUS ATTACHMENT; VIRUS INACTIVATION; VIRUS LIKE AGENT; VIRUS REACTIVATION;

ADSORPTION; ANIMALS; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; BUFFERS; CHO CELLS; CHROMATOGRAPHY, ION EXCHANGE; CRICETINAE; CRICETULUS; LEUKEMIA VIRUS, MURINE; OSMOLAR CONCENTRATION; VIRUS ATTACHMENT;

CRICETULUS GRISEUS; MAMMALIA;

EID: 81455154473     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23300     Document Type: Article

References (39)

1. Ahamed T, Chilamkurthi S, Nfor BK, Verhaert PDEM, van Dedem GWK, van der Wielen LAM, Eppink MHM, van de Sandt EJAX, Ottens M. 2008. Selection of pH-related parameters in ion-exchange chromatography using pH-gradient operations. J Chromatogr A 1194(1): 22-29.
2. Anderson KP, Lie YS, Low MA, Williams SR, Wurm FM, Dinowitz M. 1991a. Defective endogenous retrovirus-like sequences and particles of Chinese hamster ovary cells. Dev Biol Stand 75: 123-132.
3. Anderson KP, Low MA, Lie YS, Keller GA, Dinowitz M. 1991b. Endogenous origin of defective retrovirus-like particles from a recombinant Chinese hamster ovary cell line. Virology 181: 305-311.
4. Brorson K. 2007. Advances in viral clearance. Shukla AA, Etzel M, Gadam S, editors. Process scale bioseparations for the biopharmaceutical industry. Boca Raton, FL: Taylor and Francis. p 449-462.
5. Brorson K, de Wit C, Hamilton E, Mustafa M, Swann PG, Kiss R, Taticek R, Polastri G, Stein KE, Xu Y. 2002. Impact of cell culture process changes on endogenous retrovirus expression. Biotechnol Bioeng 80(3): 257-267.
6. Brorson K, Brown J, Hamilton E, Stein KE. 2003a. Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J Chromatogr A 989: 155-163.
7. Brorson K, Krejci S, Lee K, Hamilton E, Stein K, Xu Y. 2003b. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng 82: 321-329.
8. Brorson K, Norling L, Hamilton E, Lute S, Lee K, Curtis S, Xu Y. 2004. Current and future approaches to ensure the viral safety of biopharmaceuticals. Dev Bio 118: 17-29.
9. CHMP. (Committee for Medicinal Products for Human Use EMA) 2009. Guideline of virus safety evaluation of biotechnological investigational medicinal products. London, United Kingdom.
10. Curtis S, Lee K, Blank GS, Brorson K, Xu Y. 2003. Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode. Biotechnol Bioeng 84(2): 179-186.
11. Farshid M, Taffs RE, Scott D, Asher DM, Brorson K. 2005. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. Curr Opin Biotechnol 16: 561-567.
12. FDA (Food and Drug Administration). 1997. Points to consider in the manufacture and testing of monoclonal antibody products for human use. Rockville, MD.
13. Follman DK, Fahrner RL. 2004. Factorial screening of antibody purification processes using three chromatography steps without protein A. J Chromatogr A 1024(1-2): 79-85.
14. ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use). 1999. Q5A: Viral safety evaluation of biotechnological products derived from cell lines of human or animal origin. Geneva, Switzerland.
15. ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use). 2009. Q8 (R1): Pharmaceutical Development Revision 1. Geneva, Switzerland.
16. Kelley BD, Tobler SA, Brown P, Coffman JL, Godavarti R, Iskra T, Switzer M, Vunnum S. 2008. Weak partitioning chromatography for anion exchange purification of monoclonal antibodies. Biotechnol Bioeng 101(3): 553-566.
17. Kundun A, Reindel K. 2007. Evaluation of viral clearance in purification processes. Shukla AA, Etzel M, Gadam S, editors. Process scale bioseparations for the biopharmaceutical industry. Boca Raton, FL: Taylor and Francis. p 419-448.
18. Lau AS, Lie YS, Norling LA, Sernatinger J, Dinowitz M, Petropoulos CJ, Xu Y. 1999. Quantitative competitive reverse transcription-PCR as a method to evaluate retrovirus removal during chromatography procedures. J Biotechnol 75(2-3): 105-115.
19. Leiber MM, Benveniste RE, Livingston DM, Todaro GJ. 1973. Mammalian cells in culture frequently release type C viruses. Science 182: 56-59.
20. Lute S, Norling L, Hanson M, Emery R, Stinson D, Padua D, Blank G, Chen Q, Brorson K. 2008. Robustness of virus removal by protein A chromatography is independent of media lifetime. J Chromatogr A 1205: 17-25.
21. Miesegaes G, Lute S, Brorson K. 2010. Analysis of viral clearance unit operations for monoclonal antibodies. Biotechnol Bioeng 106(2): 238-246.
22. Miesegaes G, Bailey M, Willkommen H, Chen Q, Roush D, Blümel J, Brorson K. editors. 2011. Viral Clearance Symposium 2009: International Symposium, Indianapolis, Ind.: Proceedings. Indianapolis, Indiana.
23. Norling L, Lute S, Emery R, Khuu W, Voisard M, Xu Y, Chen Q, Blank G, Brorson K. 2005. Impact of multiple re-use of anion exchange chromatography media on virus removal. J Chromatogr A 2005: 79-89.
24. Pabst TM, Suda EJ, Thomas KE, Mensah P, Ramasubramanyan N, Gustafson ME, Hunter AK. 2009. Binding and elution behavior of proteins on strong cation exchangers. J Chromatogr A 1216(45): 7950-7956.
25. Romanowski P, Schleh M, Rajurs V, Chinniah S, Dehghani H. 2008. Variables affecting titer and long-term stability of virus stocks. Bioprocess Int 6(2): 44-52.
26. Shi L, Chen Q, Norling LA, Lau AS, Krejci S, Xu Y. 2004. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification. Biotechnol Bioeng 87(7): 884-896.
27. Shukla AA, Bae SS, Moore JA, Cramer SM. 1998. Structural characteristics of low-molecular-mass displacers for cation-exchange chromatography: II. Role of the stationary phase. J Chromatogr A 827(2): 295-310.
28. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies-Application of platform approaches. J Chromatogr B 848(1): 28-39.
29. Staby A, Sand M-B, Hansen RG, Jacobsen JH, Andersen LA, Gerstenberg M, Bruus UK, Jensen IH. 2005. Comparison of chromatographic ion-exchange resins IV. Strong and weak cation-exchange resins and heparin resins. J Chromatogr A 1069: 65-77.
30. Staby A, Jacobsen JH, Hansen RG, Bruus UK, Jensen IH. 2006. Comparison of chromatographic ion-exchange resins: V. Strong and weak cation-exchange resins. J Chromatogr A 1118(2): 168-179.
31. Stein A, Kiesewetter A. 2007. Cation exchange chromatography in antibody purification: pH screening for optimised binding and HCP removal. J Chromatogr B 848(1): 151-158.
32. Strauss DM, Gorrell J, Plancarte M, Blank G, Chen Q, Yang B. 2009a. Anion exchange chromatography provides a robust, predictible process to ensure viral safety of biotechnology products. Biotechnol Bioeng 102: 168-175.
33. Strauss DM, Lute S, Brorson K, Blank GS, Chen Q, Yang B. 2009b. Removal of endogenous retrovirus-like particles from CHO-cell derived products using Q sepharose fast flow chromatography. Biotechnol Prog 25(4): 1194-1197.
34. Strauss DM, Lute S, Tebaykina Z, Frey DD, Ho C, Blank GS, Brorson K, Chen Q, Yang B. 2009c. Understanding the mechanism of virus removal by Q Sepharose Fast Flow chromatography during the purification of CHO-cell derived biotherapeutics. Biotechnol Bioeng 104(2): 371-380.
35. Strauss DM, Cano T, Cai N, Delucchi H, Plancarte M, Coleman D, Blank GS, Chen Q, Yang B. 2010. Strategies for developing design spaces for viral clearance by anion exchange chromatography during monoclonal antibody production. Biotechnol Prog 26(3): 750-755.
36. Yigzaw Y, Hinckley P, Hewig A, Vedantham G. 2009. Ion exchange chromatography of proteins and clearance of aggregates. Curr Pharm Biotechnol 10: 421-426.
37. Zhang M, Lute S, Norling L, Hong C, Safta A, O'Connor D, Bernstein LJ, Wang H, Blank G, Brorson K, Chen Q. 2009. A novel, Q-PCR based approach to measuring endogenous retroviral clearance by capture protein A chromatography. Biotechnol Bioeng 102(5): 1438-1447.
38. Zhou J, Tressel T. 2006. Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnol Prog 22: 341-349.
39. Zhou J, Tressel T, Gottschalk U, Solamo F, Pastor A, Dermawan S, Hong T, Reif O, Mora J, Hutchinson F, Murphy M. 2006. New Q membrane scale-down model for process-scale antibody production. J Chromatogr A 1134: 66-73.